Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

KAPA

Kairos Pharma (KAPA)

Kairos Pharma Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:KAPA
DateTimeSourceHeadlineSymbolCompany
19/02/202500:30Business WireKairos Pharma Announces New Department of Defense Funding for Research of ENV205AMEX:KAPAKairos Pharma Ltd
12/02/202500:30Business WireKairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical TrialAMEX:KAPAKairos Pharma Ltd
11/02/202508:45Edgar (US Regulatory)Form DEF 14C - Other definitive information statementsAMEX:KAPAKairos Pharma Ltd
07/02/202501:00Edgar (US Regulatory)Form 8-K - Current reportAMEX:KAPAKairos Pharma Ltd
07/02/202500:30Business WireKairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound’s Potential as a Therapeutic for Melanoma and GlioblastomaAMEX:KAPAKairos Pharma Ltd
05/02/202522:15Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]AMEX:KAPAKairos Pharma Ltd
05/02/202516:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:KAPAKairos Pharma Ltd
29/01/202523:22Edgar (US Regulatory)Form PRE 14C - Other preliminary information statementsAMEX:KAPAKairos Pharma Ltd
29/01/202522:39Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933AMEX:KAPAKairos Pharma Ltd
29/01/202508:10Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesAMEX:KAPAKairos Pharma Ltd
29/01/202500:15Business WireKairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024AMEX:KAPAKairos Pharma Ltd
22/01/202500:30Business WireKairos Pharma Provides Business Update and Outlook into 2025AMEX:KAPAKairos Pharma Ltd
18/01/202509:20Edgar (US Regulatory)Form 8-K - Current reportAMEX:KAPAKairos Pharma Ltd
15/01/202501:41Edgar (US Regulatory)Form 8-K - Current reportAMEX:KAPAKairos Pharma Ltd
08/01/202500:15Business WireKairos Pharma to Present at the Lytham Partners Investor Healthcare SummitAMEX:KAPAKairos Pharma Ltd
14/12/202408:10Edgar (US Regulatory)Form 8-K - Current reportAMEX:KAPAKairos Pharma Ltd
04/12/202400:30Business WireKairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical TrialAMEX:KAPAKairos Pharma Ltd
20/11/202400:48Edgar (US Regulatory)Form 8-K - Current reportAMEX:KAPAKairos Pharma Ltd
15/11/202406:19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:KAPAKairos Pharma Ltd
11/10/202408:30Edgar (US Regulatory)Form 8-K - Current reportAMEX:KAPAKairos Pharma Ltd
05/10/202407:29Edgar (US Regulatory)Form 8-K - Current reportAMEX:KAPAKairos Pharma Ltd
28/09/202407:17Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansAMEX:KAPAKairos Pharma Ltd
28/09/202407:10Edgar (US Regulatory)Form 8-K - Current reportAMEX:KAPAKairos Pharma Ltd
25/09/202411:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:KAPAKairos Pharma Ltd
25/09/202406:22Edgar (US Regulatory)Form 8-K - Current reportAMEX:KAPAKairos Pharma Ltd
18/09/202406:15Edgar (US Regulatory)Form 8-K - Current reportAMEX:KAPAKairos Pharma Ltd
17/09/202420:36Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]AMEX:KAPAKairos Pharma Ltd
17/09/202414:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:KAPAKairos Pharma Ltd
 Showing the most relevant articles for your search:AMEX:KAPA